ABSTRACT
Objective: To study the effects of glycosaminoglycan from scallop skirt (SS-GAG) on the expression of vascular endothelial growth factor (VEGF) and the mechanism of anti-atherosclerosis action of SS-GAG. Methods: U937 cells were incubated with 80mg/L oxidized low density lipoprotein (ox-LDL) for 48h to establish a macrophage-derived foam cell model. In addition, U937 cells were divided into 6 groups: ①control group; ②ox-LDL group; ③ox-LDL+200mg/L SS-GAG group; ④ox-LDL+400 mg/L SS-GAG group; ⑤ox-LDL+800 mg/L SS-GAG group; ⑥ox-LDL +Heparin 100 mg/L group.After 48h's incubation, the concentration of VEGF in the medium was determined by ELISA. Results: The expression of VEGF in U937 foam cells was obviously higher than that of the control group. After treatment with heparin (100 mg/L) and SS-GAG of different concentrations (200mg/L, 400 mg/L, 800 mg/L), the expression of VEGF decreased obviously, especially in the ox-LDL+800 mg/L SS-GAG group (P＜0.01). Conclusion: The antiatherogenic effect of SS-GAG is probably due to its ability to inhibit VEGF expression.
ABSTRACT
Objective: To study the effects of glycosaminoglycan from scallop skirt (SS-GAG) on the expression of vascular endothelial growth factor (VEGF) and the mechanism of anti-atherosclerosis action of SS-GAG. Methods: U937 cells were incubated with 80mg/L oxidized low density lipoprotein (ox-LDL) for 48h to establish a macrophage-derived foam cell model. In addition, U937 cells were divided into 6 groups: ①control group; ②ox-LDL group; ③ox-LDL+200mg/L SS-GAG group; ④ox-LDL+400 mg/L SS-GAG group; ⑤ox-LDL+800 mg/L SS-GAG group; ⑥ox-LDL +Heparin 100 mg/L group.After 48h's incubation, the concentration of VEGF in the medium was determined by ELISA. Results: The expression of VEGF in U937 foam cells was obviously higher than that of the control group. After treatment with heparin (100 mg/L) and SS-GAG of different concentrations (200mg/L, 400 mg/L, 800 mg/L), the expression of VEGF decreased obviously, especially in the ox-LDL+800 mg/L SS-GAG group (P＜0.01). Conclusion: The antiatherogenic effect of SS-GAG is probably due to its ability to inhibit VEGF expression.
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the indications of uvulopalatopharyngoplasty (UPPP) and clinical staging for oropharyngeal narrow in patients with obstructive sleep apnea hypopnea syndrome (OSAHS).</p><p><b>METHOD</b>Sixty-six OSAHS patients were retrospectively analyzed, the data of physical examination and clinical staging for oropharyngeal narrow were built based on body mass index (BMI), palate-tongue position, tonsil sizes and hypertrophy degree in lateral side of oropharynx. The patients who had palatine-tongue position in degree 1 to 2 (no significant tongue enlargement) were defined as stage I (32 cases). The patients who had palatine-tongue position in degree 3 to 4 (tongue enlargement) were defined as stage II (34 cases). Among them, the patients with tonsil sizes 0 to 1 were stage I a (5 cases) and stage IIa (10 cases), another group with tonsil size 2 to 4 were stage I b (27 cases) and stage II b (24 cases), respectively. The indications of UPPP were evaluated according to the results of polysomnography (PSG) before and after operation.</p><p><b>RESULTS</b>PSG in 1 to 2 years after operation showed: the surgical efficiency of UPPP had not any difference (P > 0.05) among different groups with the severity of OSAHS(labeled in preoperational AHI and LSaO2). Surgical results was better in patients with BMI < 30 kg/m2 (P = 0.023). Success of operation was defined as postoperational AHI <20/h and reduced more than 50% compared to preoperational AHI and symptoms alleviated significantly. Successful rates of UPPP in stage I b (70.4%, 19/27 cases) were statistically higher than that of other groups (I a:0%; I b:70. 4%; II a:20.0%; II b: 16.7%).</p><p><b>CONCLUSIONS</b>Clinical staging system for oropharyngeal narrow is based on palate-tongue position and tonsil size. It is helpful to choose the surgical indications of UPPP for patients with OSAHS. It is the best UPPP indication for stage I b patients who had no tongue enlargement (palatine-tongue position 1 to 2) and accompanied with enlargement of tonsil size (in degree 2 to 4) and their sleep breathing disorder could be alleviated through UPPP.</p>